Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation

J. Feucht; L. Joachim; P. Lang; T. Feuchtinger

doi:10.1055/s-0033-1333749

Klin Padiatr 2013; 225(03): 164-169
DOI: 10.1055/s-0033-1333749

Review

Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation

Adoptiver T-Zell-Transfer bei refraktären Virusinfektionen mit CMV, EBV oder ADV nach allogener Stammzelltransplantation

Authors

J. Feucht

¹Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
L. Joachim

¹Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
P. Lang

¹Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany
T. Feuchtinger

¹Pediatric Hematology/Oncology, University Children’s Hospital Tübingen, Germany

Abstract

Viral infections after allogeneic stem cell transplantation (SCT) are an important cause of morbidity and mortality as SCT can expose patients to a transient state of combined immunodeficieny. Most viral infections after SCT are caused by the endogenous reactivation of persistent pathogens such as adenovirus (ADV), cytomegalovirus (CMV), and Epstein-Barr-virus (EBV). The control of these infections will ultimately depend on the restoration of adequate T-cell immunity.

Zusammenfassung

Nach allogener Blutstammzelltransplantation (SCT) stellen Virusinfektionen eine wichtige Ursache für lebensbedrohliche Zustände dar, die meist mit einem passageren kombinierten Immundefekt einhergehen. Mehrheitlich handelt es sich hierbei um die Reaktivierung persistierender Pathogene wie Adenoviren (ADV), Cytomegalie-Virus (CMV) oder Epstein-Barr-Virus (EBV). Die Kontrolle dieser Infektionen hängt wesentlich von der adäquaten Erholung der T-Zell-Funktion ab.

Key words

virus infection - allogeneic stem cell transplantation - T-cell transfer

Schlüsselwörter

Virusinfektion - allogene Stammzelltransplantation - T-Zell-Transfer

Full Text

References

References
1 Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008
2 Einsele H, Hebart H, Kauffmann-Schneider C et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763
3 Schuster FR, Simon A, Laws HJ et al. Viral infections in pediatric cancer patients. Klin Padiatr 2005; 217 (Suppl. 01) S67-S84
4 Mohty M, Jacot W, Faucher C et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2003; 17: 2168-2177
5 Kapp M, Tan SM, Einsele H et al. Adoptive immunotherapy of HCMV infection. Cytotherapy 2007; 9: 699-711
6 Koehl U, Dirkwinkel E, Koenig M et al. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr 2008; 220: 348-352
7 Flomenberg P, Babbitt J, Drobyski WR et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169: 775-781
8 Shields AF, Hackman RC, Fife KH et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985; 312: 529-533
9 Feuchtinger T, Lang P, Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma 2007; 48: 244-255
10 La Rosa AM, Champlin RE, Mirza N et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32: 871-876
11 Feuchtinger T, Richard C, Pfeiffer M et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Klin Padiatr 2005; 217: 339-344
12 Echavarria M, Forman M, van Tol MJ et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358: 384-385
13 Lion T, Baumgartinger R, Watzinger F et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102: 1114-1120
14 Ocheni S, Kroeger N, Zabelina T et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42: 181-186
15 Handgretinger R, Lang P, Schumm M et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci 2001; 938: 340-357; discussion 57–58
16 Chiusolo P, Metafuni E, Cattani P et al. Prospective Evaluation of Epstein-Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy. J Clin Immunol 2010; 30: 894-902
17 Tran H, Nourse J, Hall S et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261-281
18 Buyck HC, Ball S, Junagade P et al. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009; 43: 813-816
19 Bahceci E, Epperson D, Douek DC et al. Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. British journal of haematology 2003; 122: 934-943
20 Lewin SR, Heller G, Zhang L et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002; 100: 2235-2242
21 Wagner HJ, Cheng YC, Huls MH et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981
22 Meij P, van Esser JW, Niesters HG et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297
23 van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972-978
24 Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008
25 Heslop HE, Li C, Krance RA et al. Epstein-Barr infection after bone marrow transplantation. Blood 1994; 83: 1706-1708
26 Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010; 10: 337-351
27 Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044
28 Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922
29 Peggs KS, Verfuerth S, Pizzey A et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377
30 Micklethwaite KP, Clancy L, Sandher U et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974-3981
31 Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13
32 Gattinoni L, Klebanoff CA, Palmer DC et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626
33 Feuchtinger T, Opherk K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367
34 Feuchtinger T, Matthes-Martin S, Richard C et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. British journal of haematology 2006; 134: 64-76
35 Cobbold M, Khan N, Pourgheysari B et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386
36 Schmitt A, Tonn T, Busch DH et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51: 591-599
37 Uhlin M, Gertow J, Uzunel M et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2012; 55: 1064-1073
38 Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555
39 Einsele H, Rauser G, Grigoleit U et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy 2002; 4: 49-54
40 Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166
41 Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241
42 Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191
43 Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935
44 Haque T, Wilkie GM, Taylor C et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-442
45 Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131
46 Icheva V, Kayser S, Wolff D et al. Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. J Clin Oncol 2013; 31: 39-48
47 Feuchtinger T, Richard C, Pfeiffer M et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: An update. Klinische Padiatr 2005; 217: 339-344
48 Leen AM, Christin A, Myers GD et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114: 4283-4292